非小细胞肺癌中长非编码RNA:预防治疗耐药性的含义
Wenjuan Liu1, Bingli Zuo2, Wenting Liu3
1Shandong Provincial Key Laboratory of Radiation Oncology, Cancer Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong Province 250117, China.
Biochimica et biophysica acta. Reviews on cancer
|September 21, 2023
概括
长非编码RNAs (lncRNAs) 显示为早期肺癌检测和预测治疗结果的生物标志物具有前途. 了解lncRNA的作用对于改善非小细胞肺癌治疗反应至关重要.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 全球肺癌的死亡率很高,目前的治疗方法在晚期往往由于耐药性和转移而失败.
- 现有的非小细胞肺癌 (NSCLC) 治疗疗法有效性有限,这凸显了对新型诊断和治疗策略的需求.
- 长非编码RNAs (lncRNAs) 越来越多地被认为对癌症的发展和进展起着重要的作用.
研究的目的:
- 审查最近关于lncRNAs在非小细胞肺癌 (NSCLC) 治疗反应中的功能和机制的发现.
- 突出 lncRNAs 作为肺癌早期诊断和预后生物标志物的潜力.
- 探索ncRNAs作为克服NSCLC治疗耐药性的潜在治疗点.
主要方法:
- 关于NSCLC中lncRNAs的最近研究的文献综述.
- 分析与癌症治疗相关的细胞机制中的lncRNA作用.
- 关于 lncRNAs 的诊断和预后价值的证据综合.
主要成果:
- 实质性的证据支持lncRNAs在肺癌中的诊断和预后价值.
- lncRNAs涉及各种机制,影响对放射治疗,化疗和免疫治疗的反应.
- 已经确定了特定的lncRNAs,可以调节对NSCLC治疗的敏感性或耐药性.
结论:
- lncRNAs代表了改善肺癌诊断和治疗策略的有前途的分子类.
- 对lncRNA机制的进一步研究可能会导致开发针对NSCLC的新型向疗法.
- 向lncRNAs可能会提高现有治疗方法的疗效,并改善非小细胞肺癌患者的治疗结果.
相关概念视频
lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
Types of RNA
5.8K
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in regulating gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA Performs Diverse...
RNA Performs Diverse...
5.8K
Non-LTR Retrotransposons
11.6K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.6K
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
siRNA - Small Interfering RNAs
16.8K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.8K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


